Skip to main content

How a patient with a rare cancer accessed life-saving therapy through Rx4U

 Introduction

Rare diseases are, in most cases, serious, chronic, debilitating and life-threatening illnesses, which affects a small portion of people compared to other highly prevalent diseases affecting the general population. Due to this, there are various challenges pertaining to diagnosis and treatment including the involved costs. i  Rare cancers are tumors that occur infrequently in the general population and can develop in people of any age group.ii

Understanding the Challenge of Rare Cancer Treatments

Due to the lower prevalence of rare cancers, there is shortage of accessible cancer registries and tissue banks, along with limited data published for their diagnosis and treatment, along with limited availability of the necessary clinical skill set to manage the rare diseases. This leads to late or incorrect diagnosis, lower confidence in clinical decision making and possible indifference in developing new drugs.2 Furthermore, there are challenges with investments in drug development and regulatory hurdles which affect the patient outcomes.2,iii

When Access Becomes the Biggest Barrier

  • Patients with rare cancers might face delays in diagnosis, leading to late-stage presentation.3

  • However limited R&D funding and lack of comprehensive genomic profiling leads to unavailability of robust evidence which slows down the clinical trails and drug development. This coupled with stringent regulatory requirements hinder access to precision therapies as they might not be available locally.1,3

Introducing Rx4U: A Lifeline for Patients with Limited Options

  • In India, patients can obtain rare cancer therapies through the Rx4U Named Patient Purchase (NPP) program, a dedicated platform which enables access to globally sourced rare disease therapies and medications not locally approved. iv

  • Rx4U ensures the legal and regulated supply of small quantityv of high‑quality medicines, supporting improved treatment outcomes for patients with rare diseases.4

The Patient’s Journey: From Diagnosis to Desperation

Many patients with rare cancers experience prolonged diagnostic delays and limited treatment options, often exhausting standard therapies and facing increasing urgency for access to innovative treatments3 that are available elsewhere but not locally approved — a scenario where NPP pathways become a crucial avenue for accessing potentially life-saving medicines.vi

Connecting with Rx4U: How the Process Begins

  • Once a physician determines that all local therapies have been exhausted and identifies a suitable globally approved drug, the patient or caregiver contacts Rx4U to initiate an NPP access.6

  • Rx4u works as a support system and procures rare disease medications from distributor via their global supply network.5

  • This requires submitting medical documentation and prescription details, starting the formal application process for import.5

Navigating the Named Patient Program (NPP) Pathway: The Rx4u way

Named Patient Programs are regulated by national health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India’s Central Drugs Standard Control Organization (CDSCO). Rx4u plays a crucial role in bridging the gap between patients in need and the cutting-edge treatments which are not yet available in their country. 6

Securing Regulatory and Import Approvals

  • Rx4u assists healthcare providers and patients to understand and comply with the regulatory requirements of Named Patient Programs.

Coordinating with Global Manufacturers and Distributors

  • Rx4u works with regulators, pharmaceutical companies, authorized distributors and healthcare providers to obtain the necessary authentic medications.

The Role of Rx4U’s Medical and Logistics Teams

  • Manages the import process to ensure the safe, timely delivery of authentic medicines directly to patient’s doorstep.

Emotional and Practical Support for Patients and Families

  • Offers continuous support and guidance to patients and caregivers throughout the process.

Receiving the Treatment: From Hope to Healing

  • Instead of delaying treatment until a drug is available locally, NPPs enable early access through importation—an important factor in improving patient outcomes.

Outcomes: The Impact of Access on Survival and Quality of Life

  • Case reports/case series on rare disease medications received via named patient program have shown successful disease resolution in four studies and symptom improvement in 35/46 studies. Due to this demonstration of favourable efficacy in the context of rare diseases, a significant proportion of these drugs subsequently received marketing approval.vii

  • Rare disease therapy is also shown to improve vision and motor function, quality of life and survival, while reducing disease symptoms and slowing progressionviii

Key Learnings from the Case: Policy, Speed, and Compassion

Various factors critical to building sustainable healthcare systems for timely management of rare diseases via compassionate use need to incorporate: 6

  • Integrating rare disease management into public health policies, global collaboration, patient advocacy, improvement of access to diagnostic tools, and investment in research and education, and sharing of information.6

Turning Hope into Action for Rare Disease Patients

For those living with rare and serious conditions, finding effective treatment can feel overwhelming. Limited options often mean delays and uncertainty—but hope doesn’t have to stop there.

Platforms like Rx4u make access to rare medicines simpler and faster, bridging the gap between patients and lifesaving therapies. By removing barriers and streamlining the process, Rx4u turns hope into action—bringing essential treatments within reach and offering a real chance at recovery.

Comments

Post a Comment

Popular posts from this blog

Global Access to Radicut: How the Named Patient Program Supports Patients

Introduction   Ra dicut ®  ( Eda ra vone )  is a medicine first developed in Japan to help patients recovering from acute ischemic stroke. It works by reducing harmful free  ra dicals and has been used since 2001 to manage stroke-related neurological symptoms. 1   Because of its protective effect on nerve cells, Japanese doctors suggested that it might also help people with ALS/MND. This led to clinical trials by Mitsubishi Tanabe Pharma, the makers of  Ra dicut . 1 ,2   Why  RA DICUT  Access Is Limited Globally   RA DICUT   represents  one of the few  disease modifying  the ra pies for Amyotrophic Late ra l Sclerosis (ALS), a progressive neurodegene ra tive disease. 3   However, despite its potential, access to  RA DICUT   remains  highly variable worldwide for seve ra l reasons:   Regulatory approvals are f ra gmented. Although  Ra dicut  has been approved  for ALS in countrie...
Post a Comment
Read more

Top 5 Myths about Named Patient Import in India

  When it comes to accessing life-saving or rare medicines that aren’t yet available in India, the process of named patient import often feels confusing. Many people hear bits and pieces, through friends, social media, or word of mouth, and end up with half-truths or misconceptions. These myths can create unnecessary confusion, stress, and even delay treatment for patients who need it the most.    In this blog, we’re breaking down the top five myths about named patient import in India so you can see the process more clearly and confidently.   Named Patient Import Is Illegal in India   The idea that NPI is against the law is one of the most widespread misconceptions. In reality, there are clear provisions under the Drugs and Cosmetics Act 1940 and Rules 1945 that make it possible to import medicines when needed. Applications can be made to the Drug Controller General of India by patients, hospitals, or pharmaceutical companies. Globally too, similar progr...
Post a Comment
Read more

Benlysta: What you need to know

Introduction: Overview of Benlysta and Its Role in Autoimmune Disease Treatment   Autoimmune diseases develop when the immune system, which normally protects us from infections, mistakenly attacks the body’s own healthy tissues . 1 In systemic lupus erythematosus (SLE, or “lupus”), this abnormal response can cause widespread inflammation and damage to multiple organs. 2 For many years, treatment has relied on traditional immunosuppressive medications that broadly reduce immune activity. While these drugs can help control disease symptoms, patients often require long-term, high-dose therapy. This can weaken the body’s defences , making patients vulnerable to serious infections and increasing their long-term risk of certain types of cancer . In addition, many of these medications are associated with significant side effects that can limit their us e .   T hus , targeted biologic therapies aim to interfere with key immune pathways , potentially resulting in fewer side effects. 3...
Post a Comment
Read more